Accordingly, vague resistance to anti-angiogenic therapy by VEGFA signaling blockade was found to be responsible for the upregulation of Ang-2 in late stage pancreatic neuroendocrine tumors [35]. Here, VEGFA is linked to pancreatic neuroendocrine tumor.